In the pursuit of market outperformance, investors navigate the landscape of stock selection. The right picks can play a pivotal role in enhancing your wealth.
Mineralys Therapeutics Inc (NASDAQ: MLYS) closed the day trading at $13.34 down -2.06% from the previous closing price of $13.62. In other words, the price has decreased by -$2.06 from its previous closing price. On the day, 0.75 million shares were traded. MLYS stock price reached its highest trading level at $13.9 during the session, while it also had its lowest trading level at $13.29.
Ratios:
For a better understanding of MLYS, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 26.48 and its Current Ratio is at 26.48. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Jefferies on June 11, 2025, initiated with a Hold rating and assigned the stock a target price of $15.
On July 10, 2024, H.C. Wainwright started tracking the stock assigning a Buy rating and target price of $30.
On April 02, 2024, Goldman started tracking the stock assigning a Buy rating and target price of $30.Goldman initiated its Buy rating on April 02, 2024, with a $30 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Jul 11 ’25 when Congleton Jon sold 15,884 shares for $14.51 per share. The transaction valued at 230,431 led to the insider holds 846,405 shares of the business.
Levy Adam Scott sold 10,758 shares of MLYS for $155,454 on Jul 11 ’25. The CFO and Secretary now owns 206,612 shares after completing the transaction at $14.45 per share. On Jul 14 ’25, another insider, Rodman David Malcom, who serves as the Chief Medical Officer of the company, sold 11,366 shares for $14.59 each. As a result, the insider received 165,879 and left with 97,907 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, MLYS now has a Market Capitalization of 869438528 and an Enterprise Value of 544661440.
Stock Price History:
The Beta on a monthly basis for MLYS is -0.31, which has changed by -0.029818177 over the last 52 weeks, in comparison to a change of 0.16260707 over the same period for the S&P500. Over the past 52 weeks, MLYS has reached a high of $18.38, while it has fallen to a 52-week low of $8.24. The 50-Day Moving Average of the stock is -9.97%, while the 200-Day Moving Average is calculated to be 1.59%.
Shares Statistics:
Over the past 3-months, MLYS traded about 794.22K shares per day on average, while over the past 10 days, MLYS traded about 658490 shares per day. A total of 64.88M shares are outstanding, with a floating share count of 40.63M. Insiders hold about 37.65% of the company’s shares, while institutions hold 65.93% stake in the company. Shares short for MLYS as of 1751241600 were 7667206 with a Short Ratio of 9.65, compared to 1748563200 on 6163892. Therefore, it implies a Short% of Shares Outstanding of 7667206 and a Short% of Float of 15.55.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
